Stocklytics Platform
Asset logo for symbol XGN
Exagen
XGN59
$4.10arrow_drop_up6.12%$0.24
Penny Stock
Asset logo for symbol XGN
XGN59

$4.10

arrow_drop_up6.12%

Performance History

Chart placeholder
Key Stats
Open$3.95
Prev. Close$3.92
EPS-0.94
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$72.31M
PE Ratio-
LOWHIGH
Day Range3.71
4.39
52 Week Range1.30
4.91
Ratios
EPS-0.94

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Exagen (XGN)

Exagen Inc (XGN) is a company that specializes in the development and commercialization of innovative diagnostic tests for autoimmune diseases. They focus on providing accurate and timely information to physicians to assist in the diagnosis and treatment of these conditions. The company's flagship product is AVISE CTD, a comprehensive panel of tests that aids in the diagnosis of systemic lupus erythematosus (SLE) and other related autoimmune diseases. This test is designed to provide physicians with valuable information to guide their treatment decisions and improve patient outcomes.
In terms of stock price history, Exagen Inc (XGN) has shown steady growth over the past few years. The stock has consistently outperformed the broader market and has delivered strong returns to investors. This positive performance can be attributed to the company's strong financials and the growing demand for their diagnostic tests. Investors have recognized the potential of Exagen Inc (XGN) and have shown confidence in the company's ability to deliver value. As a result, the stock price has witnessed significant appreciation.
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. John Aballi
Headquarters
Vista
Employees
199
Exchange
NASDAQ
add Exagen  to watchlist

Keep an eye on Exagen

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Exagen 's (XGN) price per share?

The current price per share for Exagen (XGN) is $4.1. The stock has seen a price change of $0.24 recently, indicating a 6.12% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Exagen (XGN)?

For Exagen (XGN), the 52-week high is $4.91, which is 19.85% from the current price. The 52-week low is $1.3, the current price is 215.38% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Exagen (XGN) a growth stock?

Exagen (XGN) has shown an average price growth of -4.13% over the past three years. It has received a score of 66 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Exagen as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Exagen (XGN) stock price performance year to date (YTD)?

As of the latest data, Exagen (XGN) has a year-to-date price change of 108.12%. Over the past month, the stock has experienced a price change of 49.69%. Over the last three months, the change has been 31.41%. Over the past six months, the figure is 105%. Looking at a longer horizon, the five-year price change stands at -77.22%.
help

Is Exagen (XGN) a profitable company?

Exagen (XGN) has a net income of -$23.69M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 56.06% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -17.17% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $52.55M, with a revenue growth rate of 15.33%, providing insight into the company's sales performance and growth. The gross profit is $29.46M. Operating income is noted at -$22.84M. Furthermore, the EBITDA is -$13.81M.
help

What is the market capitalization of Exagen (XGN)?

Exagen (XGN) has a market capitalization of $72.31M. The average daily trading volume is 4.2, indicating the stock's liquidity and investor engagement.

News

Take Your Investments to a Whole New Level